Dementia Associated With Alzheimer's Disease - Pipeline Review, H1 2016

  • ID: 3734767
  • Report
  • 77 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AgeneBio Inc.
  • Boehringer Ingelheim GmbH
  • Eisai Co., Ltd.
  • H. Lundbeck A/S
  • MediPost Co., Ltd.
  • Neurodyn Inc.
  • MORE
Dementia Associated With Alzheimer's Disease - Pipeline Review, H1 2016

Summary

‘Dementia Associated With Alzheimer's Disease - Pipeline Review, H1 2016’, provides an overview of the Dementia Associated With Alzheimer's Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dementia Associated With Alzheimer's Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dementia Associated With Alzheimer's Disease and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Dementia Associated With Alzheimer's Disease
- The report reviews pipeline therapeutics for Dementia Associated With Alzheimer's Disease by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Dementia Associated With Alzheimer's Disease therapeutics and enlists all their major and minor projects
- The report assesses Dementia Associated With Alzheimer's Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Dementia Associated With Alzheimer's Disease

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Dementia Associated With Alzheimer's Disease
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Dementia Associated With Alzheimer's Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AgeneBio Inc.
  • Boehringer Ingelheim GmbH
  • Eisai Co., Ltd.
  • H. Lundbeck A/S
  • MediPost Co., Ltd.
  • Neurodyn Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Dementia Associated With Alzheimer's Disease Overview

Therapeutics Development

Pipeline Products for Dementia Associated With Alzheimer's Disease - Overview

Pipeline Products for Dementia Associated With Alzheimer's Disease - Comparative Analysis

Dementia Associated With Alzheimer's Disease - Therapeutics under Development by Companies

Dementia Associated With Alzheimer's Disease - Therapeutics under Investigation by Universities/Institutes

Dementia Associated With Alzheimer's Disease - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Unknown Stage Products

Dementia Associated With Alzheimer's Disease - Products under Development by Companies

Dementia Associated With Alzheimer's Disease - Products under Investigation by Universities/Institutes

Dementia Associated With Alzheimer's Disease - Companies Involved in Therapeutics Development

Adamas Pharmaceuticals, Inc.

AgeneBio Inc.

Amarantus Bioscience Holdings, Inc.

Boehringer Ingelheim GmbH

Chase Pharmaceuticals Corporation

Eisai Co., Ltd.

FORUM Pharmaceuticals Inc.

H. Lundbeck A/S

MediPost Co., Ltd.

Neurodyn Inc.

Dementia Associated With Alzheimer's Disease - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(donepezil hydrochloride + memantine hydrochloride ER) - Drug Profile

Product Description

Mechanism of Action

R&D Progress

BI-409306 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CPC-201 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

E-2609 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

eltoprazine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

encenicline hydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Gln-1062 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

levetiracetam - Drug Profile

Product Description

Mechanism of Action

R&D Progress

LUAF-20513 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Neurostem - Drug Profile

Product Description

Mechanism of Action

R&D Progress

salicylamine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

TAK-070 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Dementia Associated With Alzheimer's Disease - Recent Pipeline Updates

Dementia Associated With Alzheimer's Disease - Dormant Projects

Dementia Associated With Alzheimer's Disease - Discontinued Products

Dementia Associated With Alzheimer's Disease - Product Development Milestones

Featured News & Press Releases

Dec 08, 2015: Amarantus Announces Positive Phase 2 Data for Eltoprazine in Alzheimer's Aggression

Sep 15, 2015: NIH Awards $7.5 Million Grant for AgeneBio HOPE4MCI Phase 3 Clinical Trial to Delay the Onset of Alzheimer's Dementia

Mar 11, 2015: AgeneBio Announces Publication of Phase 2 Clinical Trial Results for New Approach to Delaying the Onset of Alzheimer’s Dementia

Jan 28, 2015: AgeneBio Receives Grant from Alzheimer’s Drug Discovery Foundation for New Approach to Delaying the Onset of Alzheimer’s Dementia

May 20, 2014: Adamas Pharmaceuticals Receives $25 Million Milestone Payment From Forest Laboratories

May 15, 2012: Adamas Announces Successful End-Of-Phase II Meeting With FDA For Arimenda

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Dementia Associated With Alzheimer's Disease, H1 2016

Number of Products under Development for Dementia Associated With Alzheimer's Disease - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Comparative Analysis by Unknown Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Dementia Associated With Alzheimer's Disease - Pipeline by Adamas Pharmaceuticals, Inc., H1 2016

Dementia Associated With Alzheimer's Disease - Pipeline by AgeneBio Inc., H1 2016

Dementia Associated With Alzheimer's Disease - Pipeline by Amarantus Bioscience Holdings, Inc., H1 2016

Dementia Associated With Alzheimer's Disease - Pipeline by Boehringer Ingelheim GmbH, H1 2016

Dementia Associated With Alzheimer's Disease - Pipeline by Chase Pharmaceuticals Corporation, H1 2016

Dementia Associated With Alzheimer's Disease - Pipeline by Eisai Co., Ltd., H1 2016

Dementia Associated With Alzheimer's Disease - Pipeline by FORUM Pharmaceuticals Inc., H1 2016

Dementia Associated With Alzheimer's Disease - Pipeline by H. Lundbeck A/S, H1 2016

Dementia Associated With Alzheimer's Disease - Pipeline by MediPost Co., Ltd., H1 2016

Dementia Associated With Alzheimer's Disease - Pipeline by Neurodyn Inc., H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Dementia Associated With Alzheimer's Disease Therapeutics - Recent Pipeline Updates, H1 2016

Dementia Associated With Alzheimer's Disease - Dormant Projects, H1 2016

Dementia Associated With Alzheimer's Disease - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Dementia Associated With Alzheimer's Disease, H1 2016

Number of Products under Development for Dementia Associated With Alzheimer's Disease - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Adamas Pharmaceuticals, Inc.
AgeneBio Inc.
Amarantus Bioscience Holdings, Inc.
Boehringer Ingelheim GmbH
Chase Pharmaceuticals Corporation
Eisai Co., Ltd.
FORUM Pharmaceuticals Inc.
H. Lundbeck A/S
MediPost Co., Ltd.
Neurodyn Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll